Genitourinary Cancer

Latest News

FDA Launches Priority Review of Belzutifan for Previously Treated Advanced RCC
FDA Launches Priority Review of Belzutifan for Previously Treated Advanced RCC

September 22nd 2023

The FDA has granted belzutifan priority review designation based on data from the phase 3 LITESPARK-005 trial.

Perioperative Durvalumab Leads to Promising Event-Free Survival Rates in Muscle-Invasive Urothelial Carcinoma
Perioperative Durvalumab Leads to Promising Event-Free Survival Rates in Muscle-Invasive Urothelial Carcinoma

September 6th 2023

prostate cancer
Atezolizumab Plus Cabozantinib Meets PFS End Point in Phase 3 CONTACT-02 Trial in Hormone Therapy–Pretreated mCRPC

August 27th 2023

FDA
FDA Grants Priority Review Designation to Enzalutamide for High-Risk nmCSPC

August 25th 2023

FDA Approval
FDA Approves FoundationOne CDx as a Companion Diagnostic for Niraparib Plus Abiraterone Acetate in BRCA+ mCRPC

August 18th 2023

Latest CME Events & Activities

2nd Annual International Congress on Pediatric Oncology

View More

Community Practice Connections™: 23rd Annual International Lung Cancer Congress®

View More

PER's Breast Cancer Symposia in San Antonio

Register Now!

2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition

Register Now!

Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris

View More

BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer

View More

Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®

View More

20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

View More

9th Annual School of Gastrointestinal Oncology® (SOGO®)

Register Now!

Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings

View More

New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Register Now!

New Targets, New Treatments, and New Combinations for the Management of Advanced Prostate Cancer

View More

BURST CME™: What Is the Real Risk in Lower-Risk MDS?

View More

BURST CME™: Understanding Transfusion Dependence in Lower-Risk MDS

View More

BURST CME™: How Does Transfusion Burden Impact Real-World Outcomes in MDS?

View More

Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond

View More

A Focus on Acute Myeloid Leukemia

View More

The Latest on Acute Lymphocytic Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

Medical Crossfire®: Onco-Nursing Best Practices for Managing AEs Related to CAR T-Cell Therapy from Treatment Center to Community

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies

View More

Medical Crossfire®: Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Medical Crossfire®: Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies

View More

25th Annual International Lung Cancer Congress®

Register Now!

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

© 2023 MJH Life Sciences

All rights reserved.